Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.37 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | ELANE | P08246 | 1/20 | 0.36 |
| ▸ | RORC | P51449 | 1/20 | 0.36 |
| ▸ | MDM4 | O15151 | 2/20 | 0.36 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8272139 | 1.00 | ACHE (0.39) | ACHEALDH1A1CYP1A2CYP3A4HSD11B1 | |
| SCHEMBL12413553 | 0.88 | HSD11B1 (0.37) | ACHEHSD11B1MDM4MDM2MAPT | |
| SCHEMBL8239554 | 0.88 | PIK3CG (0.39) | HSD11B1OPRM1MAPTEGFRMAPK1 | |
| SCHEMBL12043674 | 0.81 | ACHE (0.47) | ACHEALDH1A1CYP1A2CYP3A4ELANE | |
| SCHEMBL2024709 | 0.78 | PIK3CG (0.43) | HSD11B1MAPK1 | |
| SCHEMBL2024712 | 0.78 | PIK3CG (0.43) | HSD11B1MAPK1 | |
| SCHEMBL1003751 | 0.78 | AMY1A (0.36) | ALDH1A1HSD11B1OPRM1MDM4MDM2 | |
| SCHEMBL2024711 | 0.78 | HSD11B1 (0.41) | CYP3A4HSD11B1OPRM1MAPK1 | |
| SCHEMBL8272138 | 0.78 | HSD11B1 (0.41) | CYP3A4HSD11B1OPRM1MAPK1 | |
| SCHEMBL30292878 | 0.76 | EGFR (0.45) | ACHEALDH1A1HSD11B1EGFRKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7868008-B2 | Substituted isoindolones and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2011-01-11 | — | — | US | claimed |
| US-20090111830-A1 | SUBSTITUTED ISOINDOLONES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | US | claimed |
| EP-2357169-A1 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | AstraZeneca AB (SE) | 2011-08-17 | — | — | EP | disclosed |
| US-20110166155-A1 | Substituted Isoindolones and Their Use as Metabotropic Glutamate Receptor Potentiators | VAN WAGENEN BRADFORD | 2011-07-07 | — | — | US | disclosed |
| US-7968570-B2 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2011-06-28 | — | — | US | disclosed |
| US-7868008-B2 | Substituted isoindolones and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2011-01-11 | — | — | US | disclosed |
| US-20090275578-A1 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2009-11-05 | — | — | US | disclosed |
| US-20090111830-A1 | SUBSTITUTED ISOINDOLONES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111830-A1 | SUBSTITUTED ISOINDOLONES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | GRM1, GRIN1, GRM2 | ACHE 1071/4885ALDH1A1 1757/4885CYP1A2 1320/4885 |
| US-20090275578-A1 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | GRM1, GRIN1, GRM3 | ACHE 1263/4885ALDH1A1 1582/4885CYP1A2 1256/4885 |
| US-20110166155-A1 | Substituted Isoindolones and Their Use as Metabotropic Glutamate Receptor Potentiators | GRM1, GRIN1, GRM2 | ACHE 1071/4885ALDH1A1 1757/4885CYP1A2 1320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.